TMCnet News
Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer SymposiumTempus AI, Inc. (NASDAQ: TEM) today announced that 16 abstracts leveraging its diagnostic capabilities and extensive multimodal database will be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8-11 in San Antonio. In addition, a late-breaking abstract will highlight how Tempus' multimodal oncology foundation model (oFM), trained on data from more than 1.6 million cancer patients, integrates longitudinal clinical and molecular data to identify differences in patient outcomes and potential treatment benefits in metastatic breast cancer. Breast cancer is increasingly understood as a collection of biologically distinct diseases, with treatment decisions shaped by differences in tumor biology, molecular characteristics and how cancers evolve over time. Across the studies being presented, Tempus and its research collaborators showcase how connecting molecular, clinical and real-world data can generate actionable insights into cancer biology, treatment response and patient risk. "As our understanding of breast cancer advances and treatment options expand, having the right information to guide care is more important than ever," said Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus. "By combining advanced molecular testing with our extensive multimodal database and AI, we are uncovering insights that go beyond conventional approaches to understanding cancer biology, treatment response and resistance. This research demonstrates the potential of our integrated platform to inform more personalized treatment decisions and advance cancer care." The full list of accepted abstracts include (all times CST):
December 9, 12:30 PM - 2:00 PM | Abstract Number: P1-5-27
December 9, 12:30 PM - 2:00 PM | Abstract Number: 958
December 9, 12:30 PM - 2:00 PM | Abstract Number: 827
December 9, 12:30 PM - 2:00 PM | Abstract Number: 1650
December 9, 12:30 PM - 2:00 PM | Abstract Number: 3116
December 9, 4:30 PM - 5:30 PM | Abstract # RF3-1
December 9, 5:00 PM - 6:30 PM | Abstract number: 365
December 10, 7:00 AM - 8:30 AM | Abstract Number: 2136
December 10, 7:00 AM - 8:30 AM | Abstract Number: 683
December 10, 12:30 PM - 2:00 PM | Late Breaking Abstract Number: 3439
December 10, 12:30 PM-2:00 PM | Abstract Number: 3020
December 10, 12:30 PM-2:00 PM | Abstract Number: 3009
December 10, 5:00 PM - 6:30 PM | Abstract Number: 1656
December 10, 5:00 PM - 6:30 PM | Abstract Number: 382
December 11, 12:30 PM - 2:00 PM | Abstract Number: 1251
December 11, 12:30 PM - 2:00 PM | Abstract Number: 1522
About Tempus AI
For more information, visit tempus.com and follow Tempus on LinkedIn, Instagram, and X. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261119739681/en/ |

